{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IVB+Rectal+Cancer&page=5", "query": { "condition": "Stage IVB Rectal Cancer", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 145, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IVB+Rectal+Cancer&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IVB+Rectal+Cancer&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T15:18:03.071Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01802320", "title": "Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Mucinous Adenocarcinoma", "Colon Signet Ring Cell Adenocarcinoma", "Rectal Mucinous Adenocarcinoma", "Rectal Signet Ring Cell Adenocarcinoma", "Recurrent Colon Carcinoma", "Recurrent Rectal Carcinoma", "Stage IIIA Colon Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2013-03", "completion_date": "2015-08-05", "has_results": true, "last_update_posted_date": "2019-09-20", "last_synced_at": "2026-10-07T15:18:03.071Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01802320" }, { "nct_id": "NCT04109924", "title": "TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Colorectal Carcinoma", "Metastatic Colon Adenocarcinoma", "Metastatic Rectal Adenocarcinoma", "Recurrent Colon Adenocarcinoma", "Recurrent Colorectal Adenocarcinoma", "Recurrent Rectal Adenocarcinoma", "Stage III Colon Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Stage IIIA Colon Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIB Rectal Cancer AJCC v8", "Stage IIIC Colon Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Rectal Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Stage IVC Rectal Cancer AJCC v8", "Unresectable Colon Adenocarcinoma", "Unresectable Colorectal Carcinoma", "Unresectable Rectal Adenocarcinoma" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2019-12-27", "completion_date": "2024-09-05", "has_results": true, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-10-07T15:18:03.071Z", "location_count": 4, "location_summary": "Tampa, Florida • New Brunswick, New Jersey • Buffalo, New York + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04109924" }, { "nct_id": "NCT05130060", "title": "A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Microsatellite Stable Colon Carcinoma", "Metastatic Microsatellite Stable Colorectal Carcinoma", "Metastatic Rectal Adenocarcinoma", "Microsatellite Stable Rectal Carcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Colorectal Cancer Peptide Vaccine PolyPEPI1018", "type": "BIOLOGICAL" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2022-01-10", "completion_date": "2023-06-11", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-07T15:18:03.071Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05130060" }, { "nct_id": "NCT02713373", "title": "Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Colorectal Carcinoma", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2016-08-05", "completion_date": "2021-07-20", "has_results": true, "last_update_posted_date": "2022-10-06", "last_synced_at": "2026-10-07T15:18:03.071Z", "location_count": 2, "location_summary": "Buffalo, New York • Cleveland, Ohio", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02713373" }, { "nct_id": "NCT01729923", "title": "A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Colon Carcinoma", "Recurrent Rectal Carcinoma", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2013-03", "completion_date": "2016-09-06", "has_results": true, "last_update_posted_date": "2018-01-16", "last_synced_at": "2026-10-07T15:18:03.071Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01729923" }, { "nct_id": "NCT01383343", "title": "Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Colon Carcinoma", "Recurrent Rectal Carcinoma", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Sorafenib Tosylate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2011-08", "completion_date": "2017-02", "has_results": false, "last_update_posted_date": "2017-04-19", "last_synced_at": "2026-10-07T15:18:03.071Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01383343" }, { "nct_id": "NCT02983578", "title": "Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Colorectal Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Lung Non-Small Cell Carcinoma", "Mismatch Repair Deficiency", "Refractory Colorectal Carcinoma", "Refractory Lung Carcinoma", "Refractory Pancreatic Carcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2017-03-02", "completion_date": "2025-08-30", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-10-07T15:18:03.071Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02983578" }, { "nct_id": "NCT03300609", "title": "5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Adenocarcinoma", "RAS Wild Type", "Stage III Colorectal Cancer AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7" ], "interventions": [ { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-02-27", "completion_date": "2019-10-03", "has_results": false, "last_update_posted_date": "2020-06-11", "last_synced_at": "2026-10-07T15:18:03.071Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03300609" }, { "nct_id": "NCT04761614", "title": "Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Carcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Riluzole", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Ning Jin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-04-02", "completion_date": "2023-05-06", "has_results": false, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-10-07T15:18:03.071Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04761614" }, { "nct_id": "NCT02728804", "title": "S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 380, "start_date": "2016-06-22", "completion_date": "2020-11-13", "has_results": true, "last_update_posted_date": "2023-01-26", "last_synced_at": "2026-10-07T15:18:03.071Z", "location_count": 537, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • Antioch, California + 343 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02728804" } ] }